30 April 2020
Almac Clinical Services has commenced work on numerous crucial research projects into COVID-19 treatment options for a variety of global pharmaceutical, biotech and research institutions, providing a range of solutions such as Direct to Patient, Temperature Management, Almac Adapt (JTM) and Almac OneTM, to name a few. In addition, Almac is currently in discussions with many other clients on how it can support their urgent clinical programmes. Almac continues to work with its clients in all aspects of Clinical Services, to Advance Human Health.
Almac’s global facilities remain open and operational. Almac Clinical Services has not experienced any significant operational impact due to the Coronavirus and our service levels remain unchanged. As the situation evolves, we continue to liaise with the relevant authorities to ensure successful drug delivery to patients on clinical trials.
As the global spread of COVID-19 escalates and local and national governments enhance restrictions on people’s movements, due to the essential nature of the work we carry out, Almac will continue to conduct critical business operations. Please visit our COVID-19 resource centre for more information.
We are here to help you. We invite you to bring any questions directly by contacting our Almac team if you need any help and support with your clinical services.
About Almac Clinical Services:
We currently provide services to over 600 Pharmaceutical and Biotech companies worldwide including 18 of the top 20 global pharma companies. Guided by our extensive clinical supply experience and expertise, we are recognised as one of the leading, multi-faceted, global solution providers within the niche and complex market of clinical trial supply. Our services include: